Women receive more inpatient resections and ablations for hepatocellular carcinoma than men

Table 3 Multinomial logistic regression to evaluate gender disparities in treatment for hepatocellular carcinoma^1,2

Treatment	Gender	OR	95%CI	P value
Liver transplant	Male	1.00	0.95, 1.50	0.132
	Female	1.19
Resection	Male	1.00	1.15, 1.48	< 0.001
	Female	1.31
Ablation	Male	1.00	1.02, 1.45	0.028
	Female	1.22
TACE	Male	1.00	0.84, 1.16	0.841
	Female	0.98

¹Noninvasive treatment is treated as the reference category; ²Model adjusts for age, race, primary payer, hepatitis C, hepatitis B, alcohol, NASH, primary sclerosing cholangitis, primary biliary cirrhosis, liver decompensation features, metastasis, and Elixhauser comorbidity score. NASH: Non-alcoholic steatohepatitis; TACE: Transcatheter arterial chemoembolization.